Neos Therapeutics Inc. (NASDAQ:NEOS) hit a new 52-week low during trading on Monday . The company traded as low as $6.51 and last traded at $6.57, with a volume of 58,341 shares trading hands. The stock had previously closed at $6.78.

A number of brokerages recently commented on NEOS. BMO Capital Markets reissued a “buy” rating and issued a $15.00 price objective on shares of Neos Therapeutics in a research note on Tuesday, July 19th. Wells Fargo & Co. reissued a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Finally, Royal Bank Of Canada lowered their price objective on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Neos Therapeutics has a consensus rating of “Buy” and an average price target of $21.75.

The stock’s market cap is $107.99 million. The stock has a 50 day moving average of $8.12 and a 200-day moving average of $9.39.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by $0.49. The business earned $1.49 million during the quarter, compared to the consensus estimate of $1.48 million. Equities analysts predict that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current fiscal year.

In related news, insider Juergen Martens acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were acquired at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the purchase, the insider now directly owns 10,000 shares in the company, valued at $99,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Richard I. Eisenstadt acquired 3,710 shares of the business’s stock in a transaction that occurred on Thursday, August 25th. The shares were bought at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the purchase, the chief financial officer now owns 3,710 shares of the company’s stock, valued at $25,302.20. The disclosure for this purchase can be found here.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.